COMPASS Pathways (CMPS)
(Real Time Quote from BATS)
$4.67 USD
+0.33 (7.60%)
Updated Aug 4, 2025 11:38 AM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CMPS 4.67 +0.33(7.60%)
Will CMPS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CMPS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CMPS
COMPASS Pathways (CMPS) Upgraded to Buy: Here's Why
COMPASS Pathways (CMPS) Upgraded to Buy: Here's What You Should Know
CMPS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CMPS
Compass Pathways: Overly Confident Management Or Overly Skeptical Market
Compass Pathways (CMPS) Rating Maintained at Buy by Canaccord Genuity | CMPS Stock News
Compass Pathways PLC (CMPS) Q2 2025 Earnings Call Highlights: Clinical Success and Strategic ...
Q2 2025 Compass Pathways PLC Earnings Call Transcript
Psychedelic stocks up after report on AbbVie-Gilgamesh deal talks